Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis

[1]  D. Arnold,et al.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. , 2015, New England Journal of Medicine.

[2]  B. Becher,et al.  Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells , 2014, Nature Communications.

[3]  P. Visscher,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013, Nature.

[4]  Elizabeth Whalen,et al.  Multiple Autoimmune-Associated Variants Confer Decreased IL-2R Signaling in CD4+CD25hi T Cells of Type 1 Diabetic and Multiple Sclerosis Patients , 2013, PloS one.

[5]  H. Søndergaard,et al.  Gene expression analysis of relapsing–remitting, primary progressive and secondary progressive multiple sclerosis , 2013, Multiple sclerosis.

[6]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[7]  Patrick T. Walsh,et al.  Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice , 2012, PloS one.

[8]  Bibiana Bielekova,et al.  Daclizumab Therapy for Multiple Sclerosis , 2012, Neurotherapeutics.

[9]  J. Todd,et al.  Seven newly identified loci for autoimmune thyroid disease , 2012, Human molecular genetics.

[10]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[11]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[12]  S. Baranzini,et al.  Multiple sclerosis genetics—is the glass half full, or half empty? , 2010, Nature Reviews Neurology.

[13]  B. Bielekova,et al.  An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells , 2010, The Journal of Immunology.

[14]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[15]  Xavier Montalban,et al.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.

[16]  Jing Cui,et al.  Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score , 2009, The Lancet Neurology.

[17]  Matthew Hardy,et al.  Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource , 2009, Nature Genetics.

[18]  B. Kay.  Wanted: guidelines for reporting correlations. , 2009, Advances in physiology education.

[19]  David E. Anderson,et al.  Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses1 , 2009, The Journal of Immunology.

[20]  David E. Anderson,et al.  IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production , 2009, PLoS genetics.

[21]  Mark Atkinson,et al.  Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes , 2007, Nature Genetics.

[22]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[23]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[24]  Jean Imbert,et al.  Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. , 2006, Cytokine & growth factor reviews.

[25]  J. Sprent,et al.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Roger E Bumgarner,et al.  Sample size for detecting differentially expressed genes in microarray experiments , 2004, BMC Genomics.

[28]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[29]  J. Stockman,et al.  Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study , 2009 .